Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024. In the quarter to June 2026, revenue grew 296.1%, EPS grew 96.5%, free cash flow grew 54.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

96.27 2.94 −2.96%
Market cap
$21.7B
P/E
0.0×
Fwd P/E
−35.2×
Dividend yield
—
F-score
4/9
Altman Z
9.29
Beneish M
−1.90
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 4 5 5
ROE
(165.69%) (249.28%) (294.46%) (87.22%)
ROA
(53.64%) (59.53%) (61.04%) (38.20%)
ROIC
0.00% 0.00% (1,659.95%) (329.22%)
Return on Tangible Assets
(73.79%) (89.39%) (87.36%) (67.21%)
Average Days of Receivables
53.28 84.78 79.52 69.09
Free Cash Flow per Share
(4.28) (4.86) (4.28) (3.72)
Free Cash Flow
(906.14) (967.57) (921.63) (807.67)
Other line items

Show all line items

Columns are period end dates